

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **CLEVIDIPINE INJECTABLE EMULSION OBTAINS CLINICAL TRIAL APPROVAL**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Clevidipine Injectable Emulsion (50ml:25mg, 100ml:50mg) (the “**Product**”) developed by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (石藥集團中諾藥業(石家莊)有限公司), a subsidiary of the Group, has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

Clevidipine is a dihydropyridine calcium channel blocker indicated for the treatment of hypertension when oral therapy is not feasible or not desirable. The Product, an oil-in-water emulsion, is administered by intravenous infusion. It can reduce arterial blood pressure, and its pharmacological properties including fast onset and short half-life can meet the medical needs of hypertensive emergencies and perioperative hypertension.

The Product is the first nanoemulsion formulation developed by the Group, and its clinical trial approval signifies the further enrichment of the Group’s complex formulation technology platform.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 9 January 2023

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.*